Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

Chundawat is a bioengineer and expert on protein engineering and glycosciences, the study of complex carbohydrates such as cellulose. To make the cells fluorescent and detectable by the microscope, he ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED, savolitinib and surufatinib, will be presented at the ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Real-time index price for TSX Completion Index (TXFO), along with buy or sell indicators, analysis, charts, historical ...